CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Growing awareness of personalised medicine & increasing burden of infectious diseases
4.1.2. Rising geriatric population and subsequent growth in the prevalence of chronic diseases
4.1.3. Increasing funding and research grants for the development of innovative esoteric tests
4.1.4. Rising demand for early disease detection using specialised diagnostic tests
4.1.5. Condition-specific markers and tests with advances in genomics and proteomics
4.1.6. Growth opportunities in emerging countries
4.2. Market Restraints & Challenges
4.2.1. Changing regulatory landscape
4.2.2. Unfavourable reimbursement scenario
CHAPTER 5. GLOBAL ESOTERIC TESTING MARKET – BY TYPE
5.1. Genetic Testing
5.2. Toxicology Testing
5.3. Immunology Testing
5.4. Neurology Testing
5.5. Infectious Diseases Testing
5.6. Endocrinology Testing
5.7. Oncology Testing
5.8. Others
CHAPTER 6. GLOBAL ESOTERIC TESTING MARKET – BY LABORATORY TYPE
6.1. Hospital Laboratories
6.2. Independent & Reference Laboratories
CHAPTER 7. GLOBAL ESOTERIC TESTING MARKET – BY TECHNOLOGY
7.1. Real-Time PCR
7.2. Flow Cytometry
7.3. Radioimmunoassay
7.4. Chemiluminescence Immunoassay
7.5. Enzyme-Linked Immunosorbent Assay
7.6. Mass Spectrometry
7.7. Others
CHAPTER 8. GLOBAL ESOTERIC TESTING MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL ESOTERIC TESTING MARKET - COMPANY PROFILES
9.1. ACM Global Central Laboratories, Inc.
9.2. Spectra Laboratories, Inc.
9.3. Arup Laboratories, Inc.
9.4. Miraca Holdings, Inc.
9.5. Myriad Genetics, Inc.
9.6. Sonic Healthcare Limited.
9.7. Primary Health Care, Inc.
9.8. Healthscope, Ltd.
9.9. Foundation Medicine, Inc.
9.10. Laboratory Corporation of America Holdings
9.11. OPKO Health, Inc.
9.12. Fulgent Genetics, Inc.
9.13. Invitae Corporation
9.14. Mayo Medical Laboratories
9.15. Quest Diagnostics Incorporated
CHAPTER 10. GLOBAL ESOTERIC TESTING MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
